6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide
CAS No. 342417-01-0
6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide( —— )
Catalog No. M28871 CAS No. 342417-01-0
6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide can be used in the synthesis of befetupitant and netupitant.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 45 | Get Quote |
|
10MG | 68 | Get Quote |
|
25MG | 115 | Get Quote |
|
50MG | 173 | Get Quote |
|
100MG | 258 | Get Quote |
|
200MG | 388 | Get Quote |
|
500MG | 642 | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide
-
NoteResearch use only, not for human use.
-
Brief Description6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide can be used in the synthesis of befetupitant and netupitant.
-
Description6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide can be used in the synthesis of befetupitant and netupitant.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorCCR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number342417-01-0
-
Formula Weight310.401
-
Molecular FormulaC18H22N4O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN1CCN(CC1)c1cc(c(cn1)C(N)=O)-c1ccccc1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Maria Grazia Martina, et al. Discovery of small-molecules targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases. Eur J Med Chem. 2022 Aug 29;243:114703.
molnova catalog
related products
-
72'-Dihydroxy-3'4'-d...
72'-Dihydroxy-3'4'-dimethoxyisoflavan is a natural product.
-
Lesinurad
Lesinurad is a selective inhibitor of uric acid reabsorption which is used in combination with other agents in the therapy of gout.
-
Ginsenoside F4
Ginsenoside F4 has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis, the mechanism is related to the mitochondrial dysfunction and the increase of Bax expression and decrease of Bcl-2 expression.